LEP and hepatocellular carcinoma: Recently, through in vitro studies, it has been demonstrated that the inhibition of the PI3K pathway after leptin-derived peptides (OB3) treatment plays a vital role by reducing the expression of leptin-induced proinflammatory genes in hepatocellular carcinoma cells [166].